During the past decade, Kurume University Hospital conducted 54 clinical trials. In the 10-year time frame, 54 clinical trials started and 21 clinical trials were completed, i.e. on average, 38.9% percent of trials that started reached the finish line to date. In the past 5 years, 27 clinical trials started and 16 clinical trials were completed. i.e. 59.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kurume University Hospital" #1 sponsor was "Boehringer Ingelheim" with 11 trials, followed by "Takeda" with 6 trials sponsored, "EMD Serono Research & Development Institute, Inc." with 5 trials sponsored, "Kurume University" with 4 trials sponsored and "Pfizer" with 4 trials sponsored. Other sponsors include 33 different institutions and companies that sponsored additional 30 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kurume University Hospital" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 5 trials as a collaborator, "Gilead Sciences" with 3 trials as a collaborator, "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator and "Duke Clinical Research Institute" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "Kurume University Hospital" are "Ulcerative Colitis" (5 trials), "Colitis, Ulcerative" (3 trials), "Crohn's Disease" (3 trials), "Lung Diseases, Interstitial" (3 trials) and "Muscular Atrophy, Spinal" (3 trials). Many other conditions were trialed in "Kurume University Hospital" in a lesser frequency.

Most popular intervention types in "Kurume University Hospital" are "Drug" (60 trials), "Device" (5 trials), "Other" (4 trials), "Biological" (1 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (21 trials), "Nintedanib" (5 trials), "Filgotinib" (4 trials), "Nusinersen" (3 trials) and "Apremilast" (2 trials). Other intervention names were less common.

The vast majority of trials in "Kurume University Hospital" are 67 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Kurume University Hospital". undefined are not yet recruiting, 15 are recruiting, 13 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 31 completed trials in Kurume University Hospital, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Kurume University Hospital, 2 "Phase 1" clinical trials were conducted, 16 "Phase 2" clinical trials and 39 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 4 trials that are defined as “Not Applicable".